Product
Neulasta
2 clinical trials
3 indications
Indication
Breast CancerIndication
NeutropeniaIndication
Traumatic Optic NeuropathyClinical trial
A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyStatus: Completed, Estimated PCD: 2019-09-25
Clinical trial
Principle Investigator Initiated Clinical Trial: The Neuroprotective Effect of Novel Long-acting Granulocyte-colony-stimulating Factor (PEG-GCSF) in the Traumatic Optic NeuropathyStatus: Recruiting, Estimated PCD: 2024-12-31